PATENT CLAIM ANALYSIS

Application Number: 16204964
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-06
Patent Classification: ["514", "267000"]

Abstract:
Imipridones selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and are useful for treating conditions and disorders in need of such modulation, such as cancers. Specifically, the cancer is a midline glioma, a cancer having a histone H3 mutation, or both. In addition, methods of identifying whether a subject having these conditions, is likely to be responsive to a treatment regimen, such as imipridone administration, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as imipridone administration, monitoring, or providing a prognosis for a subject with these condition are also provided.

Claim (Index 30):
The method according to  claim 21 , wherein the subject is a pediatric subject.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 98.0
- Lexical Diversity: 1.80882
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15947840', '15527982', '15998437', '14290642', '13418242']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7678818822083517
- 35 USC 102 Novelty (BERT): 0.5641285271810758
- Combined Prediction Score: 0.7475065467056242
- Mean Citation Score: 290.895
- Max Citation Score: 558.10156
- Similarity Product: 298.17508446410176

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test